About this episode: 

Sickle cell disease affects an estimated 100,000 people in the United States. Recent advancements in gene therapies and medicines like hydroxyurea are diminishing extreme pain, reducing strokes, and extending survival times for those afflicted by the disease. In this episode: leading sickle cell disease expert Dr. Mark Gladwin explains how revolutionary new treatments work and discusses the challenges to accessing life-saving care.

Guest:

Dr. Mark Gladwin is a physician-scientist and the Dean of the University of Maryland School of Medicine and Vice President for Medical Affairs at the University of Maryland, Baltimore. His research focuses include sickle cell disease and hypertension.

Host:

Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland’s Health Department.

Show links and related content:

• New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle—CNBC

• Gene Therapy: What You Need to Know—Sickle Cell Disease Association of American

• No More Pain: Breakthrough Sickle Cell Treatment from Johns Hopkins Offers Curative Potential—Johns Hopkins School of Medicine

Transcript information:

Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel.

Contact us:

Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.

Follow us:

• @‌PublicHealthPod on Bluesky

• @‌JohnsHopkinsSPH on Instagram

• @‌JohnsHopkinsSPH on Facebook

• @‌PublicHealthOnCall on YouTube

• Here's our RSS feed

Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.